MARKET

IMMP

IMMP

Immutep
NASDAQ
2.470
-0.060
-2.37%
Closed 16:00 12/02 EST
OPEN
2.530
PREV CLOSE
2.530
HIGH
2.629
LOW
2.470
VOLUME
91.44K
TURNOVER
163.40K
52 WEEK HIGH
3.640
52 WEEK LOW
1.470
MARKET CAP
213.96M
P/E (TTM)
-9.5146
1D
5D
1M
3M
1Y
5Y
'Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its LAG-3 Candidate. Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer'
Benzinga · 6d ago
BRIEF-Immutep Receives Australian Research And Development Tax Incentive
Reuters · 11/14 17:43
Immutep Receives A$986,286 Australian R&D Tax Rebate
Benzinga · 11/14 00:56
Immutep Announces Clinical Results From Phase II Trial Utilizing Its First-in-class Soluble LAG-3 Protein, Eftilagimod Alpha, In 1st Line NSCLC At SITC 2022 Annual Meeting
Benzinga · 11/10 16:12
BRIEF-Immutep Granted New Patents In Japan And South Korea
Reuters · 11/09 15:44
Immutep gets patents in Japan, South Korea linked to immunotherapy eftilagimod
Seekingalpha · 11/09 14:14
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased ...
GlobeNewswire · 11/09 13:00
Immutep Says it Was Granted Patents in Japan, South Korea for Cancer Treatments
Immutep Says it Was Granted Patents in Japan, South Korea for Cancer Treatments
MT Newswires · 11/09 12:23
More
About IMMP
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. Its other two product candidates include leramilimab (IMP701), an immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731) an immunotherapy for autoimmune diseases. The Company’s subsidiaries include Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.